Neuromuscular Diseases
Read Time: 10 mins

3,4-diaminopyridine Phosphate in the Treatment of Lambert–Eaton Myasthenic Syndrome

Copy Link
Published Online: May 2nd 2012 European Neurological Review, 2012;7(1):56–61 DOI:
Authors: Jörn Peter Sieb
Quick Links:
Article Information

3,4-diaminopyridine (3,4-DAP, amifampridine) is the leading treatment for Lambert–Eaton myasthenic syndrome (LEMS), an autoimmune disorder with impaired neuromuscular transmission, for which few effective medications are currently available. 3,4-DAP has been available as a therapy for LEMS in special treatment programmes for approximately 25 years. As an unlicensed drug, doses for oral administration are required to be compounded by local, hospital or other compounding pharmacies from the base chemical. Administering the correct dose of 3,4-DAP is critical; overdosing can increase the risk of seizures and other adverse events, while underdosing can result in a substantial loss of efficacy or even treatment failure. Two recent studies, have shown a wide variation in the 3,4-DAP content of compounded preparations (22.2–125.2 %, n=9) and (53.5–128.5 %, n=21), thereby reflecting the possibility of patients receiving dosages that might be above safety limits or even markedly below efficacy limits. This inconsistency results from the variable quality and instability of the base chemical and compounding errors. A formulation of 3,4-DAP phosphate salt has now been licensed in Europe and the US with orphan medicinal product status and appears to be as efficacious as the base in relieving the symptoms of LEMS.

Acknowledgements: Editorial assistance was provided by Touch Briefings and funded by BioMarin Europe Limited.


Amifampridine, compounded drugs, Lambert–Eaton myasthenic syndrome, potassium ion channel blockers, neuromuscular transmission, myasthenia gravis


Lambert–Eaton myasthenic syndrome (LEMS) is a rare neuromuscular disorder affecting around 1/100,000 people in Europe, although because it may go undiagnosed in many patients, its true prevalence may be considerably higher.1 LEMS results from insufficient synaptic release of acetylcholine, which disrupts peripheral cholinergic neurotransmission. This is caused by autoimmune antibodies directed against the P/Q-type voltage-gated calcium channels (VGCCs). The loss of functional VGCCs reduces the calcium-dependent quantal release of the neurotransmitter acetylcholine. This lowers the safety margin for synaptic transmission at both the neuromuscular junction and certain autonomic nerve terminals leading to muscular weakness and symptoms of autonomic dysfunction.2–5
Over half the patients with LEMS, particularly male smokers aged over 50 years, present with an underlying malignancy, usually small cell lung cancer (SCLC).6,7 However, there are also case reports on a wide variety of lung and non-lung malignancies observed in LEMS patients such as breast cancer8 and neuroblastoma.9 The peak age of onset of non-tumour LEMS is 35 years with a second peak at 60 years, whereas paraneoplastic LEMS occurs primarily in middle-aged and older adults, with a median age of onset of 58 years.10 Non-paraneoplastic LEMS can be associated with other organic-specific autoimmune disorders.11 Paraneoplastic cerebellar degeneration can also occur in cancer-associated LEMS cases.12
The diagnosis of LEMS can be challenging, since the clinical presentation of sub-acute progressive fatigue and weakness is unspecific. As a result, diagnosis is often delayed from many months up to even decades.11 The symptoms of LEMS are frequently mistaken for those of myasthenia gravis or depression. In a recent study, initial misdiagnosis occurred in 58 % of British and Dutch cases.13 The most common clinical presentation of LEMS is proximal muscle weakness (more pronounced in the hip girdle than in the shoulder girdle). Tendon reflexes are reduced or absent, but it is important to note that they may be preserved early in the course of the illness. Cranial muscles may also be involved with symptoms such as ptosis, facial weakness, dysphagia, dysarthria and difficulty chewing. Cranial muscle weakness is usually milder than in myasthenia gravis and it occurs after the onset of limb-girdle weakness. Additional symptoms of autonomic dysfunction include reduced salivation, erectile dysfunction, dryness of the eyes and reduced sweating.14 The presence of an annoying dry mouth in patients with unexplained muscular fatigability is a diagnostic ‘red flag’ for LEMS. Diagnosis of LEMS is based upon assessment of clinical symptoms in conjunction with electrophysiological parameters and antibody testing. Electrophysiology testing demonstrates the characteristic so-called Lambert triad, including:

  • reduced amplitudes of the compound muscles action potential (CMAP) in the motor conduction velocity studies;
  • decremental responses of the CMAP amplitudes to low-frequency (2–3 Hz) repetitive nerve stimulation; and
  • marked incremental responses of the CMAP amplitudes to high-frequency repetitive nerve stimulation or voluntary muscle contraction over a brief period of time.15

If the facilitation is greater than 100 % in most muscles tested or is greater than 400 % in any muscle, the patient almost certainly has LEMS. If facilitation is less than 50 % in all muscles tested, the patient still may have LEMS, especially if symptoms have been present for only a short time.4 The diagnosis of LEMS may be confirmed by radioimmunoassay of VGCC antibodies which are believed to be the main pathogenic factors in LEMS,16 and these are detected in 85 % of patients with clinically and electrophysiologically defined LEMS.17,18 In seronegative LEMS patients without detectable VGCC antibodies, the electrophysiological findings are less pronounced.19 Because of the high prevalence of SCLC in LEMS, it is mandatory to perform a careful tumour screening, especially in patients with a history of smoking. In almost all patients of a recently published Dutch cohort, SCLC was found within one year of diagnosis of the LEMS.20 Computed tomography (CT)-thorax scans detected most of the tumours found and was far more sensitive than chest X-rays.20 [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) may have an additive value in tumour screening in selected cases.
Following diagnosis of LEMS, various test instruments can be employed to measure clinical improvement, such as the Subjective Symptoms Score, LEMS Classification, Muscle Strength Score21 and Quantitative Myasthenia Gravis (QMG) Score.22,23 However, scores developed to evaluate myasthenia gravis patients are only of questionable value to document the impairment in LEMS patients especially due to autonomic dysfunction and lower limb weakness.
Current Treatments for Lambert–Eaton Myasthenic Syndrome
The most widely used treatment for symptom relief of LEMS is 3,4-diaminopyridine (3,4-DAP, amifampridine), which was first suggested to improve muscle strength and autonomic function in a small case series of LEMS patients more than 25 years ago.24
3,4-DAP blocks potassium ion channels in membranes and facilitates synaptic transmission.25 The blocking of potassium ion channels prolongs the depolarisation during nerve action potentials, thereby increasing the open-time of voltage-gated calcium channels and consequently the influx of calcium ions into the nerve terminal. This increased calcium influx enhances the quantal neurotransmitter release which is calcium dependant. Both 4-aminopyridine and 3,4-DAP have been used to treat LEMS, but 4-aminopyridine is thought to be less effective and has a narrow toxic to therapeutic margin,26 with many neurological side effects reported.27 Due to the rarity of the condition, few randomised controlled trials (RCTs) involving LEMS therapies have been conducted. The potassium channel blocker guanidine hydrochloride has shown limited efficacy in some small studies but it is associated with gastrointestinal, renal and haematological adverse events.27,28 Cholinesterase inhibitors such as pyridostigmine bromide have been employed in the treatment of myasthenia gravis for more than 50 years but have only been used in limited numbers of LEMS patients and produce only minimal to moderate responses when used as monotherapy, although they may improve dry mouth.4,27,29 A study comparing 3,4-DAP with pyridostigmine in the treatment of LEMS showed that muscle strength and CMAP were significantly improved with 3,4-DAP but not with pyridostigmine and combined treatment with both produced no advantage over 3,4-DAP alone.30 Gastrointestinal cramps and diarrhoea may occur when 3,4-DAP is taken with pyridostigmine and can be minimised by reducing the dose of pyridostigmine.4
If 3,4-DAP fails to satisfactorily control the symptoms of LEMS, immunomodulatory therapies may be considered, however, some neurologists also use immune modulation therapy prior to beginning 3,4-DAP treatment. High-dose intravenous immunoglobulin (IVIG) treatment, plasma exchange and immunoadsorption therapy have been evaluated in small trials but require much larger studies to confirm results and support their wider use.31–33 Only one RCT involving these therapies has been carried out. It compared IVIG with placebo in LEMS patients and found significant but short-term improvement of limb, respiratory and bulbar muscle strength.33 Immunosuppressive therapies such as prednisolone or azathioprine have shown efficacy in LEMS but the proportions of patients showing improvements were limited and the effects were short-lived.34–37 In LEMS patients corticosteroids can be used when required for the disease treatment; however, immunosuppressants should be avoided before the presence of a tumour is ruled out.38
As in other autoimmune disorders, the anti-CD 20 antibody rituximab is a promising agent also for LEMS. However, there are still only scattered reports on the use of rituximab in LEMS patients.35,39 A recently published retrospective data survey including ten patients with myasthenia gravis and two patients with LEMS, found that rituximab treatment resulted in a significant clinical improvement in two-thirds of cases.39 The data from this survey showed that both LEMS patients improved clinically, however, they did not achieve remission.

Anti-tumour treatments are essential for all patients with the paraneoplastic form of LEMS to treat underlying malignancies.40 Interestingly, data supports a role for the LEMS-related immune response in suppressing tumour activity which can prolong the survival time of LEMS patients with cancer.41,42 Chemotherapeutic agents, such as vincristine, doxorubicin, adriamycine and cyclophosphamide, have shown efficacy against SCLC-associated LEMS but the proportions of patients benefiting were small.34,37 Chalk et al.37 evaluated the outcome of 16 patients with LEMS associated with small-cell carcinoma. Thirteen patients received specific tumour therapy and most also received pharmacological and immunological treatment for LEMS. Seven of 11 patients surviving for more than two months after tumour therapy showed substantial neurological improvement but only one patient was in complete remission seven years after the cancer therapy. In three of these 11 patients, improvement was only transient.
Clinical Evidence Supporting the use of 3,4-diaminopyridine in Lambert–Eaton Myasthenic Syndrome
The efficacy and safety of 3,4-DAP in LEMS treatment have been investigated in several small clinical trials. Moderate to marked functional improvement was seen in patients receiving 3,4-DAP at doses of 24–80 mg/day iv or up to 102 mg/day oral in non-randomised trials (n=1–53).24,34,43–47 Six RCTs (n=7–26) compared DAP with placebo for treating LEMS over periods up to eight weeks; these are summarised in Table 1.30,48–52 3,4-DAP produced significant improvements compared with placebo in a number of criteria including the Subjective Symptoms Score, LEMS Classification, Muscle Strength Score, QMG Score and amplitudes of the CMAPs (see Figure 1).
All the studies showed that 3,4-DAP was generally well tolerated with a favourable risk:benefit ratio. Few adverse effects were reported, and these were mild, transient and dose-related, and included paraesthesia, heat sensation, difficulty sleeping, light-headedness and fatigue.53 3,4-DAP can however, increase the risk of seizure especially in patients on high daily doses (80 mg or more) and with brain metastases. Among 669 patients from a French multiple sclerosis clinic treated with 3,4-DAP, less than 20 % of patients presented with adverse drug reactions (ADRs) while using moderate doses of 3,4-DAP (either 20–30 mg daily for multiple sclerosis fatigue, or up to 80 mg daily for patients with LEMS) for periods of up to 51 months.54 In this observational, retrospective cohort study, the majority of ADRs were mild to moderate and transient or reversible at the end of treatment or after dose adjustment. Most did not require discontinuation. The most commonly observed ADRs were paraesthesias. In this study there was one case of epileptic seizure, one of hepatotoxicity and one of heart palpitations thought ‘possibly’ to be linked to 3,4-DAP. Overall, the incidence of certain side effects of 3,4-DAP is unknown due to limited clinical experiences. Because of this, treated patients must be monitored regularly including laboratory testing and an electrocardiogram (ECG) is mandatory if there is evidence of cardiac arrhythmias prior to the initiation of treatment. A recent Cochrane review55 analysed the results of four of these RCTs in a total of 54 patients with LEMS and concluded that there is limited to moderate high-quality evidence showing that 3,4-DAP for up to eight weeks or IVIG improved muscle strength scores and CMAP in LEMS.
The Problem of Compounding 3,4-diaminopyridine
The use of compounded drug products, produced by the ad hoc mixing of drugs tailored to the specialised medical need of the patient, are still widespread in independent community pharmacies.56 The practice is controversial because, by definition, it involves producing a drug for which safety and efficacy have not been demonstrated. Compounding requires high staff competency to assure the quality of the compounded medication. However, compounding pharmacies are not usually equipped to comply with Good Manufacturing Practice (GMP) standards, which require drug products to have an active ingredient range limit of 95–105 % of the declared label content.57 Compounded medications may vary significantly in dosage and absorption characteristics, with no independent check of quality or variation. This results in uncertainty in dosing and raises concerns for patient therapy.58 There are numerous published cases of problems associated with compounded drugs. The analysis of prescriptions for 0.3 % nitroglycerin ointment found that 29 % of the 24 samples were subpotent and one sample was superpotent.59 This product was widely used, with 84,000 prescriptions for this ointment written in 2004 alone. Accidental overdoses of 4-aminopyridine due to pharmacy errors have resulted in life-threatening seizures in MS patients.60,61 A survey of compounded drug products including female hormones, local anaesthetics and inhalation drugs, by the US Food and Drug Administration (FDA), found 33 % of products failed testing criteria, either due to sub- or super-potency or lack of uniformity of individual dosage units. Potency ranged from 67.5 to 268.4 % of the amount of drug declared on the product labelling.56,62,63
The quality of compounded drugs creates an important public health concern and is of particular relevance for 3,4-DAP because until recently it has only been available as a compounded product. Its use requires local, hospital or other pharmacies to prepare tablets or capsules from the base compound.64 These are used either orally or in the preparation of solutions for intravenous administration. Raust et al. demonstrated that the base form of 3,4-DAP is much less stable under stress conditions than the salt formulation of 3,4-DAP, with 27 % of the base form degraded compared with only 0.1 % of the salted form.64 As there exists potential instability of the base compound (which is only stable for up to 12 months) and potential compounding errors in manufacture, these issues have implications for the efficacy and safety of the product. Furthermore, compounded forms of 3,4-DAP do not have appropriate safety monitoring and pharmacovigilance systems in place to capture, analyse and report efficacy and safety data.
A recent study assessed the 3,4-DAP content of tablet or capsule samples prepared in nine different pharmacies in Germany (two), Italy (one), The Netherlands (one), US (four) and UK (one) that claimed to contain 5, 10, 20 or 50 mg of active drug.65 Ten samples of each preparation were analysed. The variability in dosage form weight ranged from 0.81 % relative standard deviation (RSD) to 4.82 % RSD. Among the 90 samples tested, the 3,4-DAP content varied from 22.2 to 125.2 % of the declared label content (see Figure 2) and none complied with the GMP standard range of 95–105 % of declared content. There was considerable variation of 3,4-DAP within the content of samples from the same pharmacies. All 10 of the samples from one pharmacy had active drug content well below the stated label content (35.0–57.1 %). There was no evidence of significant levels of degradation products in any of the samples. The variability in compounded 3,4-DAP samples appeared to be mostly the result of heterogeneity of the formulated material.
Similar findings were observed in another recent study of the active content variability of compounded 3,4-DAP in solid oral dosage forms, which evaluated 10 units each of 21 samples obtained from Germany (17), Belgium (two), Italy (one) and Spain (one), within the stated shelf life66 (see Figure 3). The variability in dosage form weight ranged from 1.16 % RSD to 5.48 % RSD. Among the 210 units tested, 3,4-DAP content ranged from 53.5 to 128.5 %. No dosage form achieved the GMP standard range of declared content for all ten units tested. All samples of one dosage form contained at least 10 % below the declared content (mean ± standard deviation [SD], 69.8 % ± 5.6 %), and all samples of another dosage form contained at least 10 % above the declared content (121.8 % ± 5.3 %). The most variable dosage form averaged 85.9 % of declared content but ranged from 53.5 to 118.1 %. There was no evidence of a significant presence of degradation products or related substances in 15 dosage forms. Four dosage forms contained total impurities/degradation peaks that amounted to ≤0.20 % 3,4-DAP equivalent. Two dosage forms contained higher levels of potential impurities/degradation peaks (0.43 % and 1.14 % 3,4-DAP equivalent).66
It is evident from these data that compounded formulations of 3,4-DAP can vary widely and that patients may be exposed to unnecessary risks. There is a need for pharmaceutical grade oral dosage forms of 3,4-DAP to ensure efficacy and patient safety (see Figure 3). As a result of a recent review of available efficacy and safety data, 3,4-DAP has been recommended as a first-line treatment of symptomatic LEMS by the European Federation of Neurological Societies.53 The salt species of 3,4-DAP has been shown to have superior stability compared to the base,64 and an oral formulation containing 3,4-DAP phosphate salt, equivalent to 10 mg base, is now available. This formulation has obtained the orphan medicinal product status both in the European Union and in the US, and has received marketing authorisation in Europe as Firdapse®. Although the safety and efficacy of 3,4-DAP phosphate has not been directly compared with 3,4-DAP base in a RCT, it has been shown to be essentially bioequivalent with the base preparation,67 and has been produced with vigorous quality control and pharmacovigilance standards as required by regulators.
Conclusions and Future Developments
3,4-DAP has proven to be an effective treatment of LEMS in a series of randomised studies. The tolerability has been found to be acceptable and the risk:benefit ratio was favourable. However, the variability of 3,4-DAP found in compounded preparations from different pharmacies and the associated safety risks suggest that compounding can be problematic and that approved products available as accurately measured doses may be a more effective, safe and reliable alternative. The recently licensed 3,4-DAP phosphate salt appears to be as efficacious as the base in relieving the symptoms of LEMS and has an acceptable tolerability profile. Using manufactured doses of 3,4-DAP phosphate salt avoids the problems associated with compounding at local pharmacies and increases efficacy and safety by supplying reliable and consistent doses that are within strict guidelines.
Most adverse effects associated with 3,4-DAP are dose-dependent, and the drug has a narrow therapeutic window. Possible improvement in terms of side effects and LEMS symptoms might be obtained by slow-release tablets, or a combination of 3,4-DAP with other agents. All studies on 3,4-DAP in LEMS conducted to date have included limited patient populations. More clinical trials involving larger numbers of patients are needed to support the general use of 3,4-DAP in LEMS and compare it with other treatments such as the cholinesterase inhibitors, cancer chemotherapeutic agents, immunomodulation and immunosuppression. Recently, a registry for LEMS patients was inaugurated combining patient data from several European countries. This European effort will aid in determining the frequency of adverse effects of 3,4-DAP and will hopefully lead to the improvement of therapy for LEMS patients.

Article Information:

Jörn Peter Sieb has received honoraria or consultation fees from BioMarin, Temmler and Valeant.


Jörn Peter Sieb, Department of Neurology, Grosse Parower Strasse, 18437 Stralsund, Germany. E:


The publication of this article was funded by BioMarin Europe Limited. The views and opinions expressed are those of the author and not necessarily those of BioMarin Europe Limited.


  1. Wirtz PW, van Dijk JG, van Doorn PA, et al., The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands, Neurology, 2004;63:397–8.
  2. Newsom-Davis J, The emerging diversity of neuromuscular junction disorders, Acta Myol, 2007;26:5–10.
  3. Lambert EH, Elmqvist D, Quantal components of end-plate potentials in the myasthenic syndrome, Ann N Y Acad Sci, 1971;183:183–99.
  4. Sanders DB, Lambert-Eaton myasthenic syndrome: diagnosis and treatment, Ann N Y Acad Sci, 2003;998:500–8.
  5. Nagel A, Engel AG, Lang B, et al., Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation, Ann Neurol, 1988;24:552–8.
  6. Gutmann L, Phillips LH, 2nd, Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma, Neurology, 1992;42:848–50.
  7. O'Neill JH, Murray NM, Newsom-Davis J, The Lambert-Eaton myasthenic syndrome. A review of 50 cases, Brain, 1988; 111(Pt 3):577–96.
  8. Romics L, Jr., McNamara B, Cronin PA, et al., Unusual paraneoplastic syndromes of breast carcinoma: a combination of cerebellar degeneration and Lambert-Eaton Myasthenic Syndrome, Ir J Med Sci, 2011;180:569–71.
  9. de Buys Roessingh AS, Loriot MH, Wiesenauer C, et al., Lambert-Eaton myasthenic syndrome revealing an abdominal neuroblastoma, J Pediatr Surg, 2009;44:E5–7.
  10. Gilhus NE, Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy, Autoimmune Dis, 2011;2011:973808.
  11. Pellkofer HL, Armbruster L, Krumbholz M, et al., Lamberteaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel, J Neuroimmunol, 2008;204:136–9.
  12. Mason WP, Graus F, Lang B, et al., Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert- Eaton myasthenic syndrome, Brain, 1997;120(Pt 8):1279–300.
  13. Titulaer MJ, Maddison P, Sont JK, et al., Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS, J Clin Oncol, 2011;29:902–8.
  14. O'Suilleabhain P, Low PA, Lennon VA, Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates, Neurology, 1998;50:88–93.
  15. Oh SJ, Kurokawa K, Claussen GC, et al., Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome, Muscle Nerve, 2005;32:515–20.
  16. Lennon VA, Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome, In: Robert P Lisak (ed), Handbook of Myasthenia Gravis and Myasthenic Syndromes, New York: Dekker, 1994:149–64.
  17. Motomura M, Johnston I, Lang B, et al., An improved diagnostic assay for Lambert-Eaton myasthenic syndrome, J Neurol Neurosurg Psychiatry, 1995;58:85–7.
  18. Motomura M, Lang B, Johnston I, et al., Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome, J Neurol Sci, 1997;147:35–42.
  19. Oh SJ, Hatanaka Y, Claussen GC, et al., Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome, Muscle Nerve, 2007;35:178–83.
  20. Titulaer MJ, Wirtz PW, Willems LN, et al., Screening for smallcell lung cancer: a follow-up study of patients with Lambert- Eaton myasthenic syndrome, J Clin Oncol, 2008;26:4276–81.
  21. Oh SJ, Kim DE, Kuruoglu R, et al., Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome, Muscle Nerve, 1996;19:903–6.
  22. Barohn RJ, McIntire D, Herbelin L, et al., Reliability testing of the quantitative myasthenia gravis score, Ann N Y Acad Sci, 1998;841:769–72.
  23. Bedlack RS, Simel DL, Bosworth H, et al., Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity, Neurology, 2005;64:1968–70.
  24. Lundh H, Nilsson O, Rosen I, Novel drug of choice in Eaton- Lambert syndrome, J Neurol Neurosurg Psychiatry, 1983;46:684–5.
  25. Thomsen RH, Wilson DF, Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction, J Pharmacol Exp Ther, 1983;227:260–5.
  26. Bever CT, Jr., Young D, Anderson PA, et al., The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentrationcontrolled, crossover trial, Neurology, 1994;44:1054–9.
  27. Verschuuren JJ, Wirtz PW, Titulaer MJ, et al., Available treatment options for the management of Lambert-Eaton myasthenic syndrome, Expert Opin Pharmacother, 2006;7:1323–36.
  28. Oh SJ, Kim DS, Head TC, et al., Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome, Muscle Nerve, 1997;20:1146–52.
  29. Murray NM, Newsom-Davis J, Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission, Neurology, 1981;31:265–71.
  30. Wirtz PW, Verschuuren JJ, van Dijk JG, et al., Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, doubleblind, placebo-controlled, crossover study, Clin Pharmacol Ther, 2009;86:44–8.
  31. Batchelor TT, Platten M, Hochberg FH, Immunoadsorption therapy for paraneoplastic syndromes, J Neurooncol, 1998;40:131–6.
  32. Rich MM, Teener JW, Bird SJ, Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin, Muscle Nerve, 1997;20:614–5.
  33. Bain PG, Motomura M, Newsom-Davis J, et al., Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome, Neurology, 1996;47:678–83.
  34. Tim RW, Massey JM, Sanders DB, Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment, Neurology, 2000;54:2176–8.
  35. Pellkofer HL, Voltz R, Kuempfel T, Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction, Muscle Nerve, 2009;40:305–8.
  36. Peterlin BL, Flood W, Kothari MJ, Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome, J Am Osteopath Assoc, 2002;102:682–4.
  37. Chalk CH, Murray NM, Newsom-Davis J, et al., Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma, Neurology, 1990;40:1552–6.
  38. Skeie GO, Apostolski S, Evoli A, et al., Guidelines for treatment of autoimmune neuromuscular transmission disorders, Eur J Neurol, 2010;17:893–902.
  39. Maddison P, McConville J, Farrugia ME, et al., The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome, J Neurol Neurosurg Psychiatry, 2011;82:671–3.
  40. Vedeler CA, Antoine JC, Giometto B, et al., Management of paraneoplastic neurological syndromes: report of an EFNS Task Force, Eur J Neurol, 2006;13:682–90.
  41. Titulaer MJ, Verschuuren JJ, Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms, Ann N Y Acad Sci, 2008;1132:129–34.
  42. Maddison P, Newsom-Davis J, Mills KR, et al., Favourable prognosis in Lambert-Eaton myasthenic syndrome and smallcell lung carcinoma, Lancet, 1999;353:117–8.
  43. Boerma CE, Rommes JH, van Leeuwen RB, et al., Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome, J Toxicol Clin Toxicol, 1995;33:249–51.
  44. Lundh H, Nilsson O, Rosen I, Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine, Neurology, 1984;34:1324–30.
  45. Lundh H, Nilsson O, Rosen I, et al., Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome, Acta Neurol Scand, 1993;88:136–40.
  46. Sadeh M, River Y, Argov Z, Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine, Muscle Nerve, 1997;20:735–9.
  47. Tim RW, Massey JM, Sanders DB, Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients, Ann N Y Acad Sci, 1998;841:823–6.
  48. McEvoy KM, Windebank AJ, Daube JR, et al., 3,4- Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome, N Engl J Med, 1989;321:1567–71.
  49. Oh SJ, Claussen GG, Hatanaka Y, et al., 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS, Muscle Nerve, 2009;40:795–800.
  50. Sanders DB, Howard JF, Jr., Massey JM, 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis, Ann N Y Acad Sci, 1993;681:588–90.
  51. Sanders DB, Massey JM, Sanders LL, et al., A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome, Neurology, 2000;54:603–7.
  52. Murray NM, Newsom-Davis J, Karni Y, et al., Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrom (LEMS). (Abstract), J Neurol Neurosurg Psychiatry, 1984;47:1052.
  53. Quartel A, Turbeville S, Lounsbury D, Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment, Curr Med Res Opin, 2010;26:1363–75.
  54. Flet L, Polard E, Guillard O, et al., 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study, J Neurol, 2010;257:937–46.
  55. Keogh M, Sedehizadeh S, Maddison P, Treatment for Lambert-Eaton myasthenic syndrome, Cochrane Database Syst Rev, 2011;CD003279.
  56. McPherson TB, Fontane PE, Jackson KD, et al., Prevalence of compounding in independent community pharmacy practice, J Am Pharm Assoc, 2006;46:568–73.
  57. EUR-Lex, Second Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. 1975. Available at: (accessed 22 February 2012).
  58. Goldman MP, Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?, Dermatol Surg, 2004;30:1454–6; discussion 6.
  59. Azarnoff DL, Lee JC, Lee C, et al., Quality of extemporaneously compounded nitroglycerin ointment, Dis Colon Rectum, 2007;50:509–16.
  60. Burton JM, Bell CM, Walker SE, et al., 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis, Neurology, 2008;71:1833–4.
  61. Schwam E, Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error, J Emerg Med, 2010; 41:51–4.
  62. FDA, US Food and Drug Administration. 2006 Limited FDA Survey of Compounded Drug Products. (accessed 9 February 2012).
  63. US Food and Drug Administration, Report: Limited FDA Survey of Compounded Drug Products. 2009. Available at: (accessed 22 February 2012).
  64. Raust JA, Goulay-Dufay S, Le Hoang MD, et al., Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products, J Pharm Biomed Anal, 2007;43:83–8.
  65. Green DM, Jones AC, Brain KR, Content variability of active drug substance in compounded oral 3,4-diaminopyridine products, J Clin Pharm Ther, 2012;37:53–7.
  66. Green D, Brain K, Graham R, Active content variability of compounded 3,4-Diaminopyridine in solid oral dosage forms, Presented at: TREAT-NMD Conference, 8–11 November 2011, Geneva, PCR-16.
  67. European Medicines Agency, Assessment Report for Zenas. 2009. Available at: document_library/EPAR_-_Public_assessment_report/human/001032/WC500069918.pdf (accessed 22 February 2012).

Further Resources

Share this Article
Related Content In Neuromuscular Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72